2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region
| Autor: | Sofian Johar, Jack Wei Chieh Tan, Byeong Keuk Kim, Kyung Woo Park, Dafsah Arifa Juzar, Wael Almahmeed, Michael Kang Yin Lee, Yi-Heng Li, Vinay K. Bahl, Yu-Chen Wang, Eric Oliver D. Sison, Praveen Chandra, Derek P. Chew, I. Chang Hsieh, Muhamad Ali Sk Abdul Kader, Junya Ako, Cheol Whan Lee, Doreen Su-Yin Tan, Do Quang Huan, Mark Y. Chan, Shiuan Jong Yeh, Gilles Montalescot |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Acute coronary syndrome Aspirin Prasugrel animal structures business.industry 030204 cardiovascular system & hematology Asia pacific region Clopidogrel medicine.disease 03 medical and health sciences Regimen 0302 clinical medicine P2Y12 RC666-701 medicine Diseases of the circulatory (Cardiovascular) system 030212 general & internal medicine Cardiology and Cardiovascular Medicine Intensive care medicine business Ticagrelor medicine.drug |
| Zdroj: | European Cardiology Review, Vol 16, Iss, Pp-(2021) |
| ISSN: | 1758-3756 1758-3764 |
| Popis: | The unique characteristics of patients with acute coronary syndrome in the Asia-Pacific region mean that international guidelines on the use of dual antiplatelet therapy (DAPT) cannot be routinely applied to these populations. Newer generation P2Y12 inhibitors (i.e. ticagrelor and prasugrel) have demonstrated improved clinical outcomes compared with clopidogrel. However, low numbers of Asian patients participated in pivotal studies and few regional studies comparing DAPTs have been conducted. This article aims to summarise current evidence on the use of newer generation P2Y12 inhibitors in Asian patients with acute coronary syndrome and provide recommendations to assist clinicians, especially cardiologists, in selecting a DAPT regimen. Guidance is provided on the management of ischaemic and bleeding risks, including duration of therapy, switching strategies and the management of patients with ST-elevation and non-ST-elevation MI or those requiring surgery. In particular, the need for an individualised DAPT regimen and considerations relating to switching, de-escalating, stopping or continuing DAPT beyond 12 months are discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|